8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 31, 2003

BIOANALYTICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Indiana	0-23357	35-1345024
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)
2701 Kent Avenue West Lafayette, Indiana		47906-1382
(Address of principal executive offices)		(Zip Code)
	(765) 463-4527
	(Registrant's telephone number, including area code)

Item 5.

        On October 30, 2003, Bioanalytical Systems, Inc. (the “Company”) issued the press release filed herewith as Exhibit 99.1, and incorporated herein by reference, announcing the resignation of its Chief Financial Officer, Douglas P. Wieten.

Item 7.    Financial Statements and Exhibits.

        The following exhibits are filed as a part of this report:

        (c)         Exhibits

        99.1       Press release, dated October 30, 2003, announcing the resignation of its Chief Financial Officer, Douglas P. Wieten.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  November 6, 2003 BIOANALYTICAL SYSTEMS, INC.
(Registrant)



By:  /s/ Michael P. Silvon Michael P. Silvon
Vice President, Planning and Development
Interim Chief Financial Officer and Treasurer

Exhibit Index

Item Number
assigned in
Regulation S-K Exhibit Description of Exhibits

        99 (99.1) Press release dated October 31, 2003

EX-99.1

Exhibit 99.1

Douglas P. Wieten Steps Down as Bioanalytical Systems, Inc. CFO
Friday October 31, 10:55 am ET

WEST LAFAYETTE, Ind. — (BUSINESS WIRE) — Oct. 31, 2003 — Bioanalytical Systems, Inc. (Nasdaq:BASI — News) today announced that Douglas P. Wieten is leaving his position as Chief Financial Officer and Treasurer of BASi to pursue other opportunities effective October 31, 2003. The Company has named Michael P. Silvon, Vice President, Planning and Development as interim CFO and will promptly begin a search for a permanent CFO.

Headquartered in West Lafayette, Indiana BASi provides contract development services and research equipment to pharmaceutical, medical device and biotechnology companies. These companies use BASi’s services and equipment to improve the speed and efficiency of preclinical, clinical and analytical development of their products. Scientists engaged in drug metabolism studies, pharmacokinetics and basic neuroscience research at pharmaceutical research organizations are BASi’s principal clients. BASi’s services group provides screening and pharmacological testing, preclinical/safety testing, formulation development, regulatory compliance and quality control testing.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the development of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.

Contact:
     Bioanalytical Systems, Inc.
     Michael P. Silvon, 765-497-5831
     silvon@bioanalytical.com